Drug
Toreforant clinical trials
Also written JNJ-38518168.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Janssen Research & Development, LLC (8) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses toreforant is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent AsthmaCompletedPhase 2Janssen Research & Development, LLCNCT01823016Written as JNJ-38518168
- A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With MethotrexateTerminatedPhase 2Janssen Research & Development, LLCNCT01679951Written as JNJ-38518168 (3 mg)
- A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type PsoriasisCompletedPhase 2Janssen Research & Development, LLCNCT02295865Written as JNJ-38518168 60 mg
- A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic FunctionCompletedPhase 1Janssen Research & Development, LLCNCT01863784Written as JNJ-38518168
- A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate TherapyTerminatedPhase 2Janssen Research & Development, LLCNCT01862224Written as JNJ-38518168
- A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.CompletedPhase 1Janssen Research & Development, LLCNCT01970020Written as JNJ-38518168
- Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy VolunteersCompletedPhase 1Janssen Research & Development, LLCNCT01690286Written as JNJ-38518168 3 mg
- A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis ParticipantsCompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01450982Written as JNJ-38518168 / MTX
- An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid ArthritisTerminatedPhase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00941707Written as JNJ 38518168
- A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of MidazolamCompletedPhase 1Janssen Research & Development, LLCNCT01442532Written as JNJ-38518168 (30 mg)
Codes
What other systems call toreforant · ClinicalTrials.gg INT001144
- MeSH (NLM) C000633524toreforantOne source NLM
- UNII (FDA) U6LA7G393XTOREFORANTConfirmed FDA, NLM, Wikidata
- Wikidata Q27290755toreforantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152698ToreforantOne source FDA
- DrugBank DB12522One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000633524 | toreforant | One source NLM |
| UNII (FDA) | U6LA7G393X | TOREFORANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27290755 | toreforant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152698 | Toreforant | One source FDA |
| DrugBank | DB12522 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.